^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical study of SHR-1210 combined with oxaliplatin and tigio for neoadjuvant treatment of resectable gastric cancer
Excerpt:
...PCR - PCR; Complete resection rate - Complete resection rate; ORR - ORR; DFS - DFS; Surgical complications - Surgical complications; safety - safety; The effect of programmed death ligand 1 (PD-L1) expression on the efficacy - The effect of programmed death ligand 1 (PD-L1) expression on the efficacy...
Trial ID:
Source:
Title:
A single-center, prospective, single-arm, phase II trial to evaluate the adjuvant efficacy of camrelizumab with docetaxel plus S-1 for stage III (PD-L1+/dMMR/EBV+) gastric cancer after D2 resection.
Published date:
05/25/2023
Excerpt:
Furthermore, the OS rate of 19 pts at 1/2 years was 100% and 88.9%, while the RFS rate at 1/2 years was 100% and 92.3%, respectively. The dead and recurrent cases all belonged to PD-L1 positive subgroup...Adjuvant therapy of camrelizumab with docetaxel plus S-1 shows acceptable safety and promising efficacy for PD-L1positive, dMMR, or EBV positive stage III GC pts after D2 resection.
Secondary therapy:
docetaxel
DOI:
10.1200/JCO.2023.41.16_suppl.e16089
Trial ID:
Source:
Title:
A phase I study to evaluate the safety of multiantigen stimulated tumor specific cell therapy (MASCT-I) in subjects with advanced gastric cancer.
Published date:
01/11/2021
Excerpt:
...Among the 15 patients, the longest treatment duration was 18.9 months, and the median progression-free survival (mPFS) was 3.93 months, among which, mPFS of patients with microsatellite instability is 10.23 months, mPFS of patients expressing PD-L1 is 2.35 months, which is slightly higher than the historical data of Camrelizumab alone in the treatment of advanced gastric cancer (8 weeks for mPFS)...The combination of MASCT-I and Camrelizumab in the treatment of advanced gastric cancer or gastroesophageal junction cancer is a safe treatment regimen, and its efficacy deserves further study.
Secondary therapy:
MASCT-I
Trial ID:
